Combination of macro-TSH and macroprolactinemia phenomena in a patient with autoimmune thyroiditis and vitiligo

Laboratory diagnostic methods are the main tools in the practice of a doctor of any specialty, including an endocrinologist. Factors were identified that could change the concentration of the biologically active fraction of the test substance, subsequently complicating the interpretation of laboratory results and making the right clinical decision. The literature describes a variety of circulating autoantibodies involved in binding to pituitary hormones (prolactin (PRL), thyroid-stimulating hormone (TSH), growth hormone, luteinizing, follicle-stimulating, and adrenocorticotropic hormones), hypothalamus (vasopressin and oxytocin), pancreas (insulin and glucagon) , parathyroid glands (parathyroid hormone), as well as with thyroid hormones. As a rule, the resulting macromolecules lead to an increase in laboratory parameters, in which the prevailing fraction of the hormone does not have biological activity, which determines the main problem of this phenomenon. The most common variants include immune complexes with PRL and TSH, causing the phenomena of macroprolactinemia and macrothyrotropinemia (macro-TSH-emia/macro-TSH), respectively. Most laboratory test systems used in clinical practice are capable of determining only the total amount of PRL and TSH. The presented clinical observation describes a combination of the phenomena of macro-TSH and macroprolactinemia in a patient with autoimmune thyroiditis (AIT) and vitiligo.

1. Burch HB, Clement S, Sokol MS, Landry F. Reactive hypoglycemic coma due to insulin autoimmune syndrome: case report and literature review. Am J Med. 1992;92(6):681-5. doi: https://doi.org/10.1016/0002-9343(92)90787-c

2. Sanke T, Kondo M, Moriyama Y, Nanjo K, Iwo K, Miyamura K. Glucagon binding autoantibodies in a patient with hyperthyroidism treated with methimazole. J Clin Endocrinol Metab. 1983;57(6):1140-4. doi: https://doi.org/10.1210/jcem-57-6-1140.

3. Sakata S, Nakamura S, Miura K. Autoantibodies against thyroid hormones or iodothyronine. Implications in diagnosis, thyroid function, treatment, and pathogenesis. Ann Intern Med. 1985;103(4):579-89. doi: https://doi.org/10.7326/0003-4819-103-4-579

4. Cavaco B, Leite V, Loureiro MM, Ferreira MF, Pereira MC, Santos MA, Sobrinho LG. Spontaneously occurring anti-PTH autoantibodies must be considered in the differential diagnosis of patients with elevated serum PTH levels. J Endocrinol Invest. 1999;22(11):829-34. doi: https://doi.org/10.1007/BF03343654

5. Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Med Hypotheses. 2005;65(2):287-95. doi: https://doi.org/10.1016/j.mehy.2005.02.031

6. Meyer WR, Lavy G, DeCherney AH, Visintin I, Economy K, Luborsky JL. Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin. Obstet Gynecol. 1990;75(5):795-9

7. Wilkin TJ, Voss L, Tuck A, Bullen H, Betts P. Autoantibodies to endogenous growth hormone in short children (the Wessex Growth Study). Autoimmunity. 1992;14(1):67-72. doi: https://doi.org/10.3109/08916939309077358

8. Lazarus JH, John R, Ginsberg J, Hughes IA, Shewring G, et al. Transient neonatal hyperthyrotrophinaemia: a serum abnormality due to transplacentally acquired antibody to thyroid stimulating hormone. Br Med J (Clin Res Ed). 1983;286(6365):592-4. doi: https://doi.org/10.1136/bmj.286.6365.592

9. Fetissov SO, Harro J, Jaanisk M, Järv A, Podar I, et al. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. Proc Natl Acad Sci U S A. 2005;102(41):14865-70. doi: https://doi.org/10.1073/pnas.0507204102

10. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem. 2005;42(Pt 3):175-92. doi: https://doi.org/10.1258/0004563053857969

11. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical prac- tice guideline. J. Clin. Metabol. 2011;96:273-88. doi: https://doi.org/10.1210/jc.2010-1692. http://dx.doi.org/10.1210/jc.2010-1692

12. Mel’nichenko GA, Goncharov NP, Dzeranova LK, Barmina II. Clinical and laboratory aspects of the phenomenon of macroprolactinemia. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2007;3:52-4. (in Russian)

13. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab. 1981;53(4):863-6. doi: https://doi.org/10.1210/jcem-53-4-863

14. Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin. Endocrinol. 2009;71:702–8. doi: http://dx.doi.org/10.1111/j.1365-2265.2009.03570.x

15. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin. Endocrinol. 2005;62:633–43. doi: http://dx.doi.org/10.1111/j.1365-2265.2005.02243.x

16. Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012;206(3):213.e1-5. doi: https://doi.org/10.1016/j.ajog.2011.12.010

17. Сорокин М.Ю. Феномен макротиротропинемии в современной клинической практике // Клиническая и экспериментальная тиреоидология. — 2012. — Т. 8. — No4. — С.25-26. [Sorokin MY. Makro- thyrotropinemia in clinical practic. Clinical and experimental thyroidology. 2012;8(4):25-26. (In Russ.)]. doi: https://doi.org/10.14341/ket20128425-26

18. Sakai H, Fukuda G, Suzuki N, et al. Falsely elevated thyroid-stimulating hormone (TSH) level due to macro-TSH. Endocr J. 2009;56(3):435-440. doi: https://doi.org/10.1507/endocrj.k08e-361

19. Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract Res Clin Endocrinol Metab. 2013;27(5):647-61. doi: https://doi.org/10.1016/j.beem.2013.05.011

20. Hagel L. Gel-filtration chromatography. Curr Protoc Mol Biol. 2001;Chapter 10:Unit 10.9.

21. Adachi T, Hattori N, Ishihara T, Iida H, Saito T, Miyashima S, et al. Possible involvement of matrix metalloproteinase-3 in the pathogenesis of macroprolactinaemia in some patients with rheu- matoid arthritis. Eur. J. Endocrinol. 2013;169:203-9. doi: https://dx.doi. org/10.1530/EJE-13-0170

22. De Oliveira Andrade LJ, Matos de Oliveira GC. “Incidentalormones”—Macro-hormones. SciELO. 2021. doi: https://doi.org/10.1590/SciELOPreprints.1734. preprints

23. Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños- Miranda A. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol. 2007; 34(7):1514-21

24. Balázs C, Rácz K. A makro-TSH diagnosztikus és terápiás jelentősége Hashimoto-thyreoiditises betegekben [Diagnostic and therapeutical significance of macro-TSH in patients with Hashimoto’s thyroiditis]. Orv Hetil. 2017;158(34):1346-1350. doi: https://doi.org/10.1556/650.2017.30831

25. Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin. Endocrinol. Metab. 2005;90:3036-44. doi: https://dx.doi.org/10.1210/jc.2004-1600

26. Adachi T, Hattori N, Ishihara T, Iida H, Saito T, Miyashima S, et al. Possible involvement of matrix metalloproteinase-3 in the pathogenesis of macroprolactinaemia in some patients with rheu- matoid arthritis. Eur. J. Endocrinol. 2013;169:203-9. doi: https://dx.doi. org/10.1530/EJE-13-0170

27. Hattori N, Ishihara T, Yamagami K, Shimatsu A. Macro TSH in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2015;83(6):923-30. doi: https://doi.org/10.1111/cen.12643

28. Hattori N, Ishihara T, Matsuoka N, Saito T, Shimatsu A. Anti-Thyrotropin Autoantibodies in Patients with Macro-Thyrotropin and Long-Term Changes in Macro-Thyrotropin and Serum Thyrotropin Levels. Thyroid. 2017;27(2):138-146. doi: https://doi.org/10.1089/thy.2016.0442

29. Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf). 2009;71(5):702-8. doi: https://doi.org/10.1111/j.1365-2265.2009.03570.x